PharmEasy Risk Profile

What is the share price target for PharmEasy in 2025?

With rapid digital health adoption and expanded service offerings, consensus shows PharmEasy’s share price to move between ₹7 to ₹8 in 2025. The moderation is driven by increased market share in the online pharmacy segment, expansion into diagnostic services, an augmented product ecosystem, but due to valuation drops and profitability issues.

PharmEasy – IPO Expected Date & Latest Developments

PharmEasy, the online pharmacy giant, is making moves to re-enter the IPO market after pulling back its initial offering two years ago. The company plans to present its revamped IPO strategy at its board meeting, which could involve a potential reverse merger with Thyrocare, its publicly listed subsidiary. This merger, along with its improved cash flow and restructured business model, is designed to boost investor confidence as PharmEasy aims to reduce its cash burn. Despite a decline in revenue by 14.7% in FY24, PharmEasy has successfully halved its net loss, primarily by cutting down on goodwill impairment charges. The company is focusing on sustainable growth while facing increased competition from rivals like Tata-owned 1mg and Apollo 24x7. PharmEasy plans to revisit its IPO strategy in 2025, with the board meeting in February 2025 serving as a key milestone for discussions.

Is PharmEasy Good to Buy?

PharmEasy is seen as a strong growth-oriented play in the digital healthcare space. Its aggressive market expansion, investment in technological infrastructure, and diversification of product and service offerings provide significant value drivers. Investors favoring growth and digital innovation are likely to find PharmEasy an attractive buy despite short-term margin pressures.

Who are the Promoters/Management of PharmEasy?

Mr. Dharmil Sheth: Co-founder and driving force behind the company’s aggressive market expansion strategy. Mr. Vikas Bagaria: Co-founder and CEO known for his strategic focus on digital innovation and operational excellence.